Durect
Cupertino
About Durect
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $77.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Jul 2023)
- Ticker: nasdaq:DRRX
- Website: durect.com
- Phone: +1 408-777-1417
Industries & Categories
Biotechnology, Health Diagnostics, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/durect-123977 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.